Literature DB >> 16021158

Disabling pansclerotic morphea: clinical presentation in two adults.

Sherry Henderson Maragh1, Mark D P Davis, Alison J Bruce, Audrey M Nelson.   

Abstract

Disabling pansclerotic morphea involves all layers of the skin, extending through the dermis and subcutaneous tissues to involve muscle, tendon, and bone. It is distinguished from generalized scleroderma by its lack of systemic involvement. Onset usually occurs before the age of 14 years. We describe adult-onset disabling pansclerotic morphea in two previously healthy young men. In both cases, the onset of disease was explosive, with rapid progression, widespread cutaneous involvement, and severe disablement caused by mutilating contracture deformities. Increased susceptibility of sclerodermatous tissue to recalcitrant ulceration and malignant transformation with development of nonmelanoma skin cancers was also observed. Treatment of this disease continues to present a therapeutic dilemma with only sporadic remission despite multimodality therapy.

Entities:  

Mesh:

Year:  2005        PMID: 16021158     DOI: 10.1016/j.jaad.2004.10.881

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

1.  Scleroderma Mimickers.

Authors:  Nadia D Morgan; Laura K Hummers
Journal:  Curr Treatm Opt Rheumatol       Date:  2016-02-05

2.  Squamous cell carcinoma and eosinophilia in a long-term course of pansclerotic morphea.

Authors:  Inderjote Grewal; Omar Khan; William Davis
Journal:  BMJ Case Rep       Date:  2014-10-13

3.  Clinical features of patients with morphea and the pansclerotic subtype: a cross-sectional study from the morphea in adults and children cohort.

Authors:  Andrew Kim; Nicholas Marinkovich; Rebecca Vasquez; Heidi T Jacobe
Journal:  J Rheumatol       Date:  2013-12-01       Impact factor: 4.666

4.  Resolution of pansclerotic morphea after treatment with antithymocyte globulin.

Authors:  Philip Song; Christopher Gocke; Fredrick M Wigley; Francesco Boin
Journal:  Nat Rev Rheumatol       Date:  2009-09       Impact factor: 20.543

5.  Disabling pansclerotic morphoea of childhood.

Authors:  Indirakshi Jamalpur; Harikrishna Reddy Mogili; Abhilash Koratala
Journal:  BMJ Case Rep       Date:  2018-02-17

6.  Methotrexate: an effective monotherapy for refractory generalized morphea.

Authors:  Eftychia Platsidaki; Vassiliki Tzanetakou; Anargyros Kouris; Panagiotis G Stavropoulos
Journal:  Clin Cosmet Investig Dermatol       Date:  2017-05-08

7.  Adult-onset unilateral disabling pansclerotic morphea.

Authors:  Adarshlata Singh; Kritika Singhal; Sanjiv Choudhary; Shazia Bisati; Mallika Arora
Journal:  Indian J Dermatol       Date:  2014-05       Impact factor: 1.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.